ClinicalTrials.gg
CompletedNCT00740857Updated Jun 6, 2011Results posted

Study Comparing the Efficacy of Two Ibuprofen Formulations

A Phase 4 interventional study of placebo and ibuprofen Formulation 1 in Pain, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 1 site in United States. Open to participants aged 16 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-06.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
16 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 74 studies in Pain by Pfizer — none open to participants now, none under way, none of them phase 3. Pain · Pfizer.

Enrollment
34th of 71
211 · median 202
Started
2008
with 6 others
Phase 4
7 of 74
none open now
Registered
29th of 74
by date

Among the 74 studies in Pain by Pfizer, this one is the 34th largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2008, is one of 7 in phase 4, and was the 29th registered.

Pain

10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 74 studies in Pain by Pfizer is open now. The open studies under Pain, anywhere →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 16 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 74 studies in Pain by Pfizer as a file.
02

Study summary

This is a study of healthy volunteers to compare how quickly different ibuprofen products relieve dental pain.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Dental pain analgesia
04

Who can participate

Ages eligible
16 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients with post-operative pain following surgical extraction of third molars,
  • examined by the attending dentist or physician and medically cleared to participate in the study,
  • in general good health and have no to the study or rescue medication.

Exclusion criteria

Exclusions criteria:

  • any serious medical condition,
  • acute localized dental infection at the time of surgery ,
  • females who are pregnant, lactating, of , or for less than 2 years and not using a medically approved method of .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
211 participants (actual)

Study arms

  • Placebo comparator
    1

    Drug: placebo

  • Active comparator
    2

    Drug: ibuprofen Formulation 1

  • Active comparator
    3

    Drug: ibuprofen Formulation 2

Interventions

  • Drugplacebo

    2 placebo gels capsules delivered as a single dose.

  • Drugibuprofen Formulation 1

    2 marketed ibuprofen gels

  • Drugibuprofen Formulation 2

    2 marketed ibuprofen gels

06

What researchers measure

Primary outcomes

  1. Time to Meaningful Pain Relief

    Subjects evaluated the time to "First Perceptible" Relief by depressing a stopwatch at the moment they first began to experience "perceptible" relief and the time to "Meaningful" Relief by depressing a second stopwatch at the moment they first began to experience "meaningful" relief. These times were recorded up to 6 hrs after dosing. Range: up to 6 hrs, a lower number is better.

    Time frame: 0-6 hours

Secondary outcomes

  1. Pain Intensity Difference (PID) Scores at Each Individual Time Points

    PID is based on the 4-point categorical pain severity score ranging from 0 (none) to 3 (severe), this value was derived by subtracting the score at each post-dosing time point from the baseline score, so that a higher positive value is indicative of greater improvement.

    Time frame: 0-6 hours

  2. Pain Relief (PR) Scores at Individual Time Points

    Response to the question "How much pain do you have from your starting pain?" was recorded on a 5-point categorical pain relief scale (None (0), A Little (1), Some (2), A Lot (3) or Complete (4)) at designated time points after study medication was taken.

    Time frame: 0-6 hours

  3. Time-weighted Sum of Pain Relief + Pain Intensity Difference (SPRID) From 0-2 Hours and 0-6 Hours

    SPRID is a derived endpoint from the pain relief and pain intensity difference scores from 0-2 hours and 0-6 hours. PRID=PID+Pain Relief Score. SPRID-02 range: -2 (worst) to 14 (best); SPRID 06 range: -6 (worst) to 42 (best).

    Time frame: 0-2 and 0-6 hours

  4. Pain Relief Combined With Pain Intensity Difference (PRID) Scores at Individual Time Points

    PRID (PRID=PID+PR) is a derived endpoint from the pain relief and pain intensity difference scores at each time point. Range: -1 (worst) to 7 (best).

    Time frame: 0-6 hours

  5. Time-weighted Sum of Pain Intensity Difference (SPID) From 0-2 Hours and 0-6 Hours

    SPID is a derived endpoint from the pain intensity difference scores from 0-2 hours and 0-6 hours. Range: -2 (worst) to 6 (best); -6 (worst) to 18 (best).

    Time frame: 0-2 and 0-6 hours

  6. Time-weighted Sum of Pain Relief Scores (TOTPAR) From 0-2 Hours and 0-6 Hours

    TOTPAR is a derived endpoint from the pain relief scores from 0-2 hours and 0-6 hours. Range: 0 (worst) - 8 (best); 0 (worst) - 24 (best)

    Time frame: 0-2 and 0-6 hours

  7. Time to First Perceptible Relief

    The elapsed time from dosing until the patient indicated first perceptible relief, provided the subject also indicated achieving meaningful relief.

    Time frame: 0-6 hours

07

Results

Posted Aug 12, 2010

Participant flow

Patients were recruited in the United States from August 2008 to October 2008.

Participant flow — Overall Study
MilestonePlaceboIbuprofen Formulation 1Ibuprofen Formulation 2
Started338890
Completed328890
Not completed100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryTime to Meaningful Pain Relief

Subjects evaluated the time to "First Perceptible" Relief by depressing a stopwatch at the moment they first began to experience "perceptible" relief and the time to "Meaningful" Relief by depressing a second stopwatch at the moment they first began to experience "meaningful" relief. These times were recorded up to 6 hrs after dosing. Range: up to 6 hrs, a lower number is better.

Time frame:
0-6 hours
Reported as:
Median · minutes
Time to Meaningful Pain Relief
minutesPlaceboIbuprofen Formulation 1Ibuprofen Formulation 2
Time to Meaningful Pain Relief—45.4 (41.5 to 53.5)63.6 (58.6 to 84.0)
Statistical analysis
  • Placebo vs Ibuprofen Formulation 1 · Proportional hazards model · p = <0.001Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.
  • Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · Proportional hazards model · p = 0.001Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.
  • Placebo vs Ibuprofen Formulation 2 · Proportional hazards model · p = <0.001Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.
SecondaryPain Intensity Difference (PID) Scores at Each Individual Time Points

PID is based on the 4-point categorical pain severity score ranging from 0 (none) to 3 (severe), this value was derived by subtracting the score at each post-dosing time point from the baseline score, so that a higher positive value is indicative of greater improvement.

Time frame:
0-6 hours
Reported as:
Mean · units on scale
Pain Intensity Difference (PID) Scores at Each Individual Time Points
units on scalePlaceboIbuprofen Formulation 1Ibuprofen Formulation 2
15 minutes0.1 ± 0.40.2 ± 0.50.1 ± 0.3
30 minutes0.2 ± 0.50.8 ± 0.80.5 ± 0.6
45 minutes0.3 ± 0.71.3 ± 0.80.9 ± 0.7
60 minutes0.3 ± 0.71.6 ± 0.91.2 ± 0.8
90 minutes0.2 ± 0.81.8 ± 0.91.5 ± 0.8
120 minutes0.2 ± 0.81.8 ± 0.91.7 ± 0.8
180 minutes0.3 ± 1.01.7 ± 1.01.7 ± 0.9
240 minutes0.4 ± 1.21.5 ± 1.01.5 ± 0.9
300 minutes0.2 ± 1.01.4 ± 1.01.4 ± 1.0
360 minutes0.2 ± 1.01.2 ± 1.01.3 ± 0.9
Statistical analysis
  • Placebo vs Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · ANOVA · p = 0.118With treatment, baseline Pain Severity Rating (PSR), and gender terms.
  • Placebo vs Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · ANOVA · p = <0.001With treatment, baseline Pain Severity Rating (PSR), and gender terms.
SecondaryPain Relief (PR) Scores at Individual Time Points

Response to the question "How much pain do you have from your starting pain?" was recorded on a 5-point categorical pain relief scale (None (0), A Little (1), Some (2), A Lot (3) or Complete (4)) at designated time points after study medication was taken.

Time frame:
0-6 hours
Reported as:
Mean · units on scale
Pain Relief (PR) Scores at Individual Time Points
units on scalePlaceboIbuprofen Formulation 1Ibuprofen Formulation 2
15 minutes0.2 ± 0.50.5 ± 0.80.3 ± 0.6
30 minutes0.6 ± 0.81.6 ± 1.11.0 ± 0.9
45 minutes0.8 ± 1.02.4 ± 1.11.7 ± 1.1
60 minutes0.9 ± 1.12.9 ± 1.02.1 ± 1.1
90 minutes0.8 ± 1.13.2 ± 1.02.7 ± 1.0
120 minutes0.8 ± 1.23.2 ± 1.02.9 ± 1.0
180 minutes1.0 ± 1.43.0 ± 1.12.9 ± 1.1
240 minutes1.1 ± 1.62.7 ± 1.22.7 ± 1.2
300 minutes0.8 ± 1.22.5 ± 1.42.6 ± 1.3
360 minutes0.8 ± 1.32.2 ± 1.32.6 ± 1.3
Statistical analysis
  • Placebo vs Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · ANOVA · p = 0.041With treatment, baseline Pain Severity Rating (PSR), and gender terms.
  • Placebo vs Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · ANOVA · p = <0.001With treatment, baseline Pain Severity Rating (PSR), and gender terms.
SecondaryTime-weighted Sum of Pain Relief + Pain Intensity Difference (SPRID) From 0-2 Hours and 0-6 Hours

SPRID is a derived endpoint from the pain relief and pain intensity difference scores from 0-2 hours and 0-6 hours. PRID=PID+Pain Relief Score. SPRID-02 range: -2 (worst) to 14 (best); SPRID 06 range: -6 (worst) to 42 (best).

Time frame:
0-2 and 0-6 hours
Reported as:
Mean · units on scale
Time-weighted Sum of Pain Relief + Pain Intensity Difference (SPRID) From 0-2 Hours and 0-6 Hours
units on scalePlaceboIbuprofen Formulation 1Ibuprofen Formulation 2
0-2 hours1.8 ± 2.97.8 ± 2.96.3 ± 2.6
0-6 hours6.5 ± 11.924.0 ± 10.123.0 ± 9.5
Statistical analysis
  • Placebo vs Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · ANOVA · p = <0.001With treatment, baseline Pain Severity Rating (PSR), and gender terms.
SecondaryPain Relief Combined With Pain Intensity Difference (PRID) Scores at Individual Time Points

PRID (PRID=PID+PR) is a derived endpoint from the pain relief and pain intensity difference scores at each time point. Range: -1 (worst) to 7 (best).

Time frame:
0-6 hours
Reported as:
Mean · units on scale
Pain Relief Combined With Pain Intensity Difference (PRID) Scores at Individual Time Points
units on scalePlaceboIbuprofen Formulation 1Ibuprofen Formulation 2
15 minutes0.3 ± 0.80.7 ± 1.20.4 ± 0.9
30 minutes0.8 ± 1.22.4 ± 1.81.4 ± 1.5
45 minutes1.1 ± 1.63.6 ± 1.82.5 ± 1.7
60 minutes1.2 ± 1.84.5 ± 1.83.3 ± 1.7
90 minutes1.0 ± 1.95.0 ± 1.74.2 ± 1.7
120 minutes1.0 ± 2.05.0 ± 1.84.6 ± 1.7
180 minutes1.2 ± 2.44.7 ± 2.04.6 ± 1.8
240 minutes1.5 ± 2.74.2 ± 2.14.2 ± 2.0
300 minutes1.0 ± 2.13.9 ± 2.34.0 ± 2.2
360 minutes1.0 ± 2.23.4 ± 2.33.9 ± 2.1
Statistical analysis
  • Placebo vs Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · ANOVA · p = 0.056Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.
  • Placebo vs Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · ANOVA · p = <0.001Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.
SecondaryTime-weighted Sum of Pain Intensity Difference (SPID) From 0-2 Hours and 0-6 Hours

SPID is a derived endpoint from the pain intensity difference scores from 0-2 hours and 0-6 hours. Range: -2 (worst) to 6 (best); -6 (worst) to 18 (best).

Time frame:
0-2 and 0-6 hours
Reported as:
Mean · units on scale
Time-weighted Sum of Pain Intensity Difference (SPID) From 0-2 Hours and 0-6 Hours
units on scalePlaceboIbuprofen Formulation 1Ibuprofen Formulation 2
0-2 hours0.4 ± 1.22.8 ± 1.42.2 ± 1.1
0-6 hours1.4 ± 5.28.6 ± 4.88.1 ± 4.2
Statistical analysis
  • Placebo vs Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · ANOVA · p = <0.001Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.
SecondaryTime-weighted Sum of Pain Relief Scores (TOTPAR) From 0-2 Hours and 0-6 Hours

TOTPAR is a derived endpoint from the pain relief scores from 0-2 hours and 0-6 hours. Range: 0 (worst) - 8 (best); 0 (worst) - 24 (best)

Time frame:
0-2 and 0-6 hours
Reported as:
Mean · units on scale
Time-weighted Sum of Pain Relief Scores (TOTPAR) From 0-2 Hours and 0-6 Hours
units on scalePlaceboIbuprofen Formulation 1Ibuprofen Formulation 2
0-2 hours1.4 ± 1.85.0 ± 1.74.1 ± 1.6
0-6 hours5.1 ± 7.115.4 ± 5.714.9 ± 5.8
Statistical analysis
  • Placebo vs Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · ANOVA · p = <0.001Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.
SecondaryTime to First Perceptible Relief

The elapsed time from dosing until the patient indicated first perceptible relief, provided the subject also indicated achieving meaningful relief.

Time frame:
0-6 hours
Reported as:
Median · minutes
Time to First Perceptible Relief
minutesPlaceboIbuprofen Formulation 1Ibuprofen Formulation 2
Time to First Perceptible Relief—23.7 (20.6 to 26.6)28.6 (25.9 to 31.5)
Statistical analysis
  • Placebo vs Ibuprofen Formulation 1 vs Ibuprofen Formulation 2 · proportional hazards model · p = <0.001Adjusted with treatment, baseline Pain Severity Rating (PSR), and gender terms.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/33 (0%)13/33 (39.4%)
Ibuprofen Formulation 1—0/88 (0%)2/88 (2.3%)
Ibuprofen Formulation 2—0/90 (0%)7/90 (7.8%)
Most frequent other events
Most frequent other events
EventPlaceboIbuprofen Formulation 1Ibuprofen Formulation 2
NauseaGastrointestinal disorders4/331/882/90
DizzinessNervous system disorders3/330/881/90
VomitingGastrointestinal disorders2/331/881/90
FatigueGeneral disorders1/330/880/90
HeadacheNervous system disorders1/330/881/90
SyncopeNervous system disorders1/330/880/90
Hot flushVascular disorders1/330/880/90
Dry socketInfections and infestations0/330/881/90
Procedural site reactionInjury, poisoning and procedural complications0/330/881/90

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboIbuprofen Formulation 1Ibuprofen Formulation 2Total
Mean18.8 ± 2.718.5 ± 2.519.0 ± 3.018.8 ± 2.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIbuprofen Formulation 1Ibuprofen Formulation 2Total
Female164345104
Male174545107
08

Study locations

1 site
  • Salt Lake City, Utah 84124, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2008
First posted
Aug 25, 2008
Start
Aug 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Aug 12, 2010
Last update
Jun 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00740857
First posted
Aug 25, 2008
Start date
Aug 2008
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Aug 12, 2010
Last update
Jun 6, 2011

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion